CTC and PD-L1 analysis helps detect MRD and guide therapy in colorectal cancer. Publications | June 3, 2024 ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Background In stage III colorectal cancer (CRC) patients, the extent of oxaliplatin-based adjuvant therapy remains uncertain. Approximately 25–50% of stage II–III CRC patients develop recurrence and metastasis even after comprehensive treatment, largely attributed to occult disease and minimal residual disease (MRD). Circulating tumor cells (CTCs) represent a bio-mechanistic source of extravasation leading to micro-metastatic disease. CRC patients receiving reduced adjuvant therapy (3–6 months) are known to exhibit increased CTC counts and positivity rates due to the emergence of resistant clones. Assays that detect CTCs and the expression of programmed death-ligand 1 (PD-L1) as a dynamic biomarker simultaneously have significant clinical implications, particularly when tissue biopsy samples are inadequate to identify molecular targets for immune checkpoint inhibitor (ICI) therapy. Methods In a retrospective study, 182 CRC patients were analyzed for the presence and distribution of CTCs at baseline and across follow-ups (0–4 follow-ups). Peripheral blood (1.5 ml) samples were analyzed using the CDSCO-approved OncoDiscover platform, which consists of a multifunctional magneto-nanosystem mediated by anti-epithelial cellular adhesion molecule (EpCAM) antibodies. CTCs were evaluated in patients with early-stage disease (pre- and post-treatment), progressive disease, disease-free status (DFS), and metastasis. Isolated cells were immunostained to detect CK18+, CD45-, DAPI+, and PD-L1+ expression. PD-L1 expression on CTCs was validated by analyzing the linear intensity gradients of fluorescence signals. CTCs were classified as PD-L1 negative when weak or no fluorescence signal was detected and PD-L1 positive when strong fluorescence signals were observed using automated image acquisition on a Zeiss fluorescence microscope. Results Among the cohort of 182 CRC patient samples, 128 (70.3%) showed the presence of CTCs. A fluorescence intensity-based assay was developed to evaluate PD-L1 expression as a robust functional biomarker for molecular characterization of CTCs. The distribution of CTCs ranged from 1 to 9 cells. The mean fluorescence intensity value and cut-off for PD-L1 expression in CTCs was approximately 1.02. Notably, 54 patients (42.2%) with CTCs showed positive PD-L1 expression. CTC-positive patients with PD-L1 expression were observed across all stages, including early-stage disease, progressive disease, and metastasis. Patients without detectable CTCs (n = 54, 29.7%) either had clinically stable disease or were in DFS with no radiographic evidence of disease. Conclusions PD-L1 overexpression on CTCs represents a dynamic blood-based biomarker indicating disease progression even in patients with DFS status. Enumeration of CTCs along with assessment of PD-L1 expression may enable more individualized treatment strategies for CRC patients and support better monitoring of disease progression and therapeutic response. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Get in touch with us. We'd love to hear from you! Visit us for frequently asked questions and more information. Contact us First name* Last name* Email* Phone City/Country* What are you looking for?* Book a demo Event enquiry Press or Media Enquiry Other Message* Submit Terms & Conditions | Privacy Policy We'd love to hear from you Whether it’s research, technology, or partnership opportunities, we’re here to explore what’s next—together. Write to us Our Address Visit Us Here’s where you can reach us in person. We look forward to welcoming you. US office 11842, Churchill Way, Porter Ranch, CA 91326 US Lab Pasadena Bio Collaborative Incubator, 2265 E Foothill Blvd, Pasadena, CA 91107 FAQS Frequently Asked Questions Answers to commonly asked questions about Actorius and our offerings. What does Actorius Innovations & Research do? Actorius focuses on advancing precision oncology through innovative research, diagnostics, and technology platforms. Our work is centered on understanding cancer biology in depth and translating insights into actionable outcomes. Who can reach out to Actorius? Researchers, clinicians, healthcare partners, institutions, and potential collaborators are welcome to contact us. We also engage with industry partners and organizations interested in advancing cancer diagnostics and care. How long does it take to receive a response after submitting the contact form? We typically respond within 1–2 business days. Queries that require technical or scientific review may take slightly longer, and we appreciate your patience. Can I request collaborations or partnerships through the contact form? Yes. The contact form can be used to initiate discussions around research collaborations, partnerships, or technology integrations. Please include relevant details so we can route your request appropriately. Where can I find more information about your services or products? Detailed information about our platforms, research focus, and offerings is available throughout the website. If you have a specific question not addressed online, feel free to contact us directly.

CTC profiling in peripheral and portal venous blood reveals compartment-specific differences in PD-L1 expression. Publications | August 30, 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Introduction Circulating tumor cells (CTCs) are an established biomarker for prognostication, minimal residual cellular disease (MRCD), and treatment monitoring. Portal venous blood (PVB), which directly drains gastrointestinal and hepatobiliary tumors, may contain a higher CTC population than peripheral blood (PB) and could serve as a strong predictive biomarker for postoperative relapse in resected pancreatic cancer. This study evaluates CTC enumeration, CTC clusters, and PD-L1 expression in paired PB and PVB samples. Methods In this prospective observational study, paired PB and PVB samples were collected from 12 patients with hepatobiliary, pancreatic, colorectal, and gastric malignancies during interventional procedures. CTCs were enriched and identified using validated morphological and immunophenotypic criteria. PD-L1 expression and CTC clusters were evaluated by immunostaining. Detection rates, mean CTC counts, compartment concordance, and cancer-specific differences were analyzed descriptively. Results Eleven paired samples were evaluable. CTC positivity was observed in 90.9% (10/11) of PB samples and 81.8% (9/11) of PVB samples. Mean CTC counts were identical in both compartments (1.09). PD-L1-positive CTCs were more frequently detected in PB than PVB (45.5% vs. 18.2%), with corresponding mean counts of 0.45 and 0.18, respectively. CTC clusters were identified in 18.2% of cases in both compartments. Hepatocellular carcinoma and cholangiocarcinoma demonstrated high PB-PVB concordance, whereas pancreatic and rectal cancers showed compartment-specific discordance. Single CTCs predominated in both PB (72.7%) and PVB (63.6%). Conclusion Portal venous sampling is feasible and provides CTC detection rates comparable to peripheral blood. However, PB demonstrated greater detection of PD-L1-positive CTCs, suggesting compartment-specific biological differences. Combined assessment of PB and PVB may enhance liquid biopsy characterization, particularly in gastrointestinal malignancies. Larger prospective studies are warranted to define the clinical value of dual-compartment CTC profiling. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

ML models using CTCs predict surgery and adjuvant therapy success in HNSCC. Publications | June 7, 2022 ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. Background Oncology implicates the highest precision using next-generation diagnostics and progressive therapies assisted by predictive tools. If validated clinically, machine learning (ML) can provide better insights in precision oncology. Furthermore, it may longitudinally stratify the progression of cancer disease burden in real time. We have developed a circulating tumor cells (CTCs) driven ML model as a predictor for the treatment decision strategy for both surgery and adjuvant therapy in head and neck squamous cell carcinoma (HNSCC) patients. Methods In this study, a total of 380 HNSCC patients who underwent either surgery alone or surgery plus adjuvant therapy were accounted for. CTCs in patients were stratified based on clinicopathological parameters and using the OncoDiscover platform having an anti-EpCAM antibody system regulated by the Drug Controller of India. Following this, we explored the predictive performance of the ML model on the usefulness of adjuvant therapy in HNSCC patients after the surgery. The available data was randomly divided into two subsets. First, 75% of the original data was applied for training the ML, and the rest 25% of the data was used as a test set. Survival curves were generated by the Kaplan–Meier method and calculated through the log-rank test. Results The XGBoost machine learning classifier was superior to Random Forest and SVM-based analyses in predicting the usefulness of adjuvant therapy post-surgery using CTCs alone or in combination with other clinical parameters in HNSCC patients. Machine learning algorithms were compared for predicting the accuracy of patient stratification. The results for each model were: XGBoost model (Accuracy = 0.84, ROC value = 0.73, Kappa = 0.43); Random Forest model (Accuracy = 0.81, ROC value = 0.70, Kappa = 0.41); SVM model (Accuracy = 0.76, ROC value = 0.69, Kappa = 0.40). The ROC value of the XGBoost model was highest (0.73), while the ROC value for the SVM model was lower (0.69). We observed that when CTCs were combined with clinicopathological parameters, the accuracy, kappa values, and AUC-ROC drastically improved in predicting the usefulness of adjuvant therapy post-surgery. A similar trend was observed when CTCs were combined with clinicopathological parameters in predicting the line of chemotherapy post-surgery. Conclusions ML-enabled, CTC-driven predictions can be highly accurate and ascertain the patient treatments. CTCs can be a positive predictor for selecting a patient’s treatment regimen in both surgery as well as in the type of treatment (e.g., surgery alone or surgery + adjuvant therapy). It can also be implicated to classify the patients and determine who necessitates additional adjuvant therapy. Further investigations in this direction are necessary to predict the treatment options based on ML that may improve the overall survival of cancer patients. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dynamic device captures CTCs safely, enabling monitoring and metastatic control. Publications | June 3, 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Background Primary tumors are known to shed circulating tumor cells (CTCs), promoting systemic dissemination and increasing the risk of metastasis to distant organs. Approximately 90% of cancer-related deaths are directly associated with metastasis. Several studies in animal models suggest improved overall survival following reduction in the number of CTCs in circulation. In this study, we demonstrate the capture of CTCs using a continuous blood-flow device incorporating three-dimensional glass substrates (3D GS) conjugated with affinity ligands, including anti-epithelial cell adhesion molecule (EpCAM) antibody and transferrin (Tf), in cancer patients. Methods A bi-spiral, plano-horizontal, optically transparent device fabricated from biocompatible resin with multiple channels for continuous blood flow was designed using a 3D printer. The circulation device comprised 14 loops capable of holding 17.5 mL of blood and containing 680 glass substrates (2 mm diameter) conjugated with anti-EpCAM antibody and transferrin. The system was mechanized for functional circulation using three pumps. Pyrogenicity resulting from blood passage through the device was evaluated in three New Zealand White rabbits according to ISO:10993-11 guidelines for systemic toxicity assessment. Additionally, 27 blood samples from patients with early- and late-stage cancers across nine cancer types, including colorectal, lung, breast, and ovarian cancers, were processed using the OncoDialysis assay. The cohort consisted of 48.15% male and 51.85% female patients. CTCs were captured using five glass substrates from 1.5–5 mL of blood and validated using CK18 and CD45 markers through fluorescence microscopy. Samples were also analyzed using the Drug Controller, India–approved OncoDiscover technology for comparative evaluation. Results No hemolysis was observed as a result of the device. Continuous circulation of up to 5 mL of blood successfully demonstrated CTC capture within the flow system. All rabbits remained healthy during testing, and none exhibited an individual temperature increase of 0.5°C or more compared with controls, indicating no systemic toxicity. The OncoDialysis assay detected CTCs in 48.15% of patients (n = 13/27), yielding a total of 14 CTCs (12 single CTCs and 2 clusters), with a mean CTC distribution of 0.51 per 1–5 mL of blood. The OncoDiscover platform isolated 23 CTCs (18 single CTCs and 5 clusters), with a mean CTC distribution of 0.8. A concurrence rate of 74.07% was observed between the two platforms. In 40.74% of cases (n = 11/27), CTCs were detected by both systems. Conclusions We developed a dynamic in vitro blood circulation device with demonstrated safety in animal studies, capable of selectively capturing circulating tumor cells from patient blood. Reduction of CTC burden may hold significant therapeutic potential in limiting metastatic spread and improving overall survival in epithelial-origin cancers, both in treated and untreated settings. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CaP-crowned CNT nanocapsules enable pH-triggered intracellular anticancer drug delivery. Publications | April 17, 2015 Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. We report calcium phosphate (CaP) nanocapsule–crowned multiwalled carbon nanotubes (CNT–GSH–G4–CaP) as a novel platform for the intracellular delivery of an anticancer drug. As a proof of concept, the CNT–GSH–G4–CaP system demonstrates the release of the anticancer drug doxorubicin hydrochloride (DOX) within intracellular lysosomes from the interior cavity of the CNT through pH-triggered CaP dissolution. Importantly, we found that CNTs capped with a CaP nanolid can efficiently prevent premature drug release at physiological pH, while promoting DOX release in more acidic environments, such as those found in subcellular compartments like lysosomes (pH ≈ 5.0). This “zero premature release” characteristic is of significant clinical importance for delivering cytotoxic drugs, as it helps reduce systemic toxicity and enhances the effectiveness of anticancer treatment. We envision that this pH-triggered CaP-crowned CNT nanosystem could lead to a new generation of self-regulated platforms for the intracellular delivery of a wide range of anticancer drugs. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

TSG mutations predict early relapse in mEGFR lung adenocarcinoma. Publications | March 14, 2025 Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Background: Lung adenocarcinoma frequently presents with EGFR mutations, often progressing on EGFR tyrosine kinase inhibitors (TKls) despite an initial response. Progression is frequently driven by additional genetic changes, including mutations in tumor suppressor genes (TSGs). Understanding the role of these concurrent TSG mutations can help elucidate resistance mechanisms and guide the development of more effective treatment approaches. Materials and methods: We examined survival outcomes in 483 EGFR-mutant (mEGFR) patients from the GENIE BPC non-small-cell lung cancer (SCLC) dataset. To understand the mutational landscape and clonal dynamics, whole exome sequencing (WES) was carried out on 48 tumor samples from 16 mEGFR patients at both baseline and post-relapse. A comprehensive gene panel was applied to 200 liquid biopsy samples obtained longitudinally from 25 patients to track clonal evolution. Results: mEGFR patients with co-occurring TSG mutations exhibited significantly worse outcomes. In the GENIE dataset, overall survival (OS) was shorter [51.11 versus 99.3 months; hazard ratio (HR) 1.8, confidence interval (CI) 1.22-2.75, P = 0.003] and progression-free survival (PFS) was reduced (9.83 versus 11.48 months; HR 1.4, CI 1.03-1.91, P=0.026). WES analysis revealed 17 TSG mutations that were retained and showed clonal enrichment, particularly in early relapse (progression within 10 months of TKI initiation) or intermediate-stage relapse (relapse occurred between 10 and 20 months), indicated by increased variant allele frequency and their presence was strongly linked to early relapse. Longitudinal clonal studies further confirmed that TSG mutations co-occurring with mEGFR were often truncal, predominantly in early relapsers. Survival analysis using this subset of 17 TSGs showed significantly shorter OS (55.26 versus 99.3 months; HR 1.7, CI 1.12-2.65, P = 0.011) and PFS (9.67 versus 13.12 months; HR 1.5, CI 1.08-2.10, P = 0.013). Conclusions: A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Key words: lung adenocarcinoma, tyrosine kinase inhibitor, whole exome sequencing, comprehensive gene panel, tumor suppressor genes View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover liquid biopsy enables CTC detection for cancer diagnosis and monitoring. Expert Insights | August 11, 2020 OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs track residual disease and therapy response in breast cancer patients. Publications | June 6, 2023 ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Background Breast malignancies are a leading cause of cancer-related mortalities and show an ascending incidence rate. Despite advancements in our understanding of the disease, its clinical outcome is often dismal. This largely remains owing to the characteristic wide window of relapse, spanning months to decades after primary treatment. Therefore, continuous monitoring of the disease is an offered choice to detect metastatic progression and recurrence. Circulating tumor cells (CTCs) have emerged as a powerful prognostic tool to predict the disease outcome in many epithelial cancers. CTCs are a real-time surrogate biomarker accounting for minimal residual disease (MRD) which is often missed in CT PET scanning. This leads to a progression of metastasis when the patient is often considered as 'clinically disease free'. Here, we analyzed the presence of CTCs in treatment-naive and chemo-recipient breast cancer patients. Methods In this retrospective study on 417 breast cancer patients, CTCs were isolated from 1.5 ml of blood using the Drug Controller General of India (DCGI) approved OncoDiscover CTC test. This platform contains affinity-based magnetic nanoparticles to mediate EpCAM-based CTC isolation. CTCs were detected as CK18+, DAPI+ and CD45- cells based on an automated digital imaging platform. Results 42.6% (n=178) of patients were clinically at a progressive stage (stage II and III) and treatment-naive. On the other hand, 47.4% of patients received treatment including surgery and chemotherapy. CTCs were not observed in 5.6% (n=10) of the treatment-naive population, while 32% (n=75) of patients who received therapy did not show CTCs. The mean CTC number in treatment-naive patients was 15, while the mean CTC count in patients receiving therapy was drastically reduced to 2. This implied that therapy effectively countered the tumor progression and reduced the shedding of tumor cells in circulation. The distribution of CTC in treatment-naive patients exhibited a bimodal trend centered at values of 10 and 50, suggesting two distinct populations of patients with respect to CTC count. CTC count did not show any correlation with the age in both population groups. Surprisingly, CTC count in younger patients (20-50 years) was 50% higher compared to the older population (50-75 years). Conclusions The presence of CTCs in treatment-naive, progressive breast cancer patients indicated biologically aggravated disease. Although therapeutic intervention drastically reduced the CTC burden, their presence in a large population was suggestive of an MRD and the likelihood of recurrence after discontinuation of therapy. A distinct pattern of CTC occurrences in Tx naive and Tx recipient patients suggested that CTCs can be an important clinical indicator to monitor the therapy response, progression, and residual disease. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers Publications | March 17, 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Abstract Background Urological cancers, including prostate, bladder, kidney, testicular, and penile cancers, often fail to show symptoms or show only nonspecific symptoms at early stages. This leads to delayed diagnosis, treatment decisions, and outcomes. Circulating tumor cells (CTCs) predict the outcome in metastatic prostate cancer (PC). Furthermore, in bladder cancer, CTC positivity is linked to muscle invasion, higher recurrence risk, and worse clinical outcomes. CTC PD-L1 expression could evade immune elimination. In spite of complete remission, a higher percentage of patients are known to recur in urothelial cancers. CTCs acting as minimal cellular residual disease (MCRD) are highly implicated, knowing their capacity to be dormant systemically with extravasation and invasion to distant organs. We analyzed the presence of CTCs with PD-L1 over-expression in urological cancers at baseline and follow-ups. Methods Retrospectively, a total of 359 urological cancer patients were evaluated for CTC positivity, including 307 at baseline and 52 follow-up samples. The cancer type distribution was prostate cancer (n = 139), bladder (n = 188), kidney (n = 10), testes (n = 2), penis (n = 8), urothelial (n = 12), etc. Ninety-five percent of the patients were male (n = 293) and 5% were female (n = 14), with most patients aged 61 to 80 years. CTCs expressing PD-L1, positive CTCs, and CTC clusters were analyzed using OncoDiscover® PD-L1 markers and a Zeiss fluorescence automated microscope. Demographics, cancer mean distribution, and CTC and cluster frequency were analyzed. Results Of the 359 patients, CTCs were detected in 68.2% (245/359) of patients, while PD-L1 over-expression on CTCs was present in 49.9% (179/359) of patients. However, CTC clusters were uncommon and occurred in 7.2% (26/359) of patients. Across cancer types (total CTCs = 436), prostate cancer accounted for higher CTCs with a mean CTC distribution of 2.18, while bladder was 0.74, urothelial 0.34, testes 0.18, kidney 0.74, and penis 0.38, respectively. CTC PD-L1 was highest in prostate cancer (46.1%) compared to other cancers, and CTC cluster prevalence was 1.8% in prostate cancer, urothelial (0.9%), and bladder (0.2%) cancers. In CTC-positive cases, 56.3% of patients had only one CTC, 27.8% showed two CTCs, and 8.2% had three. The mean across all patients was 0.6 for CTCs, 0.3 for CTC-PD-L1 positive, and 0.1 for clusters. Conclusions CTCs with PD-L1-positive overexpression were observed across urological cancers, being particularly higher in prostate cancer compared to bladder, kidney, and penis cancers. Many patients are known to recur in spite of complete remission, possibly due to the presence of aggressive CTCs in circulation that could evade the immune system. More studies assessing the presence of CTCs with PD-L1 expression are justified in urological cancers for minimal cellular residual disease and as prognostication. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover Available in India | Dr. Jayant Khandare Expert Insights | August 9, 20222 OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare This test is made available and accessible in India. And this is what this simple and completely painless blood test has been clinically validated in a study of thousands of patients with the support of Tata memorial hospital, now being used by many oncologists to monitor their patients so as to give their better treatment options, and to know if the cancer patient is completely disease free. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Pune start-up gets US patent for delivering drugs to site-specific organs Press Release | March 6, 2023 Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Changes in lifestyle and food habits are leading to many colon related diseases including cancers, he said. Delivery of drugs to colorectal site is most challenging as the dosage forms have to prevent the early release of drug in stomach and intestine, he said. This patent (US Patent No. 11596607) is titled "Polymer based formulation for the release of drugs and bioactives at specific GIT sites". Khandare said the technology composition does not involve cumbersome tablet processing, coating and enteric or other polymers. It also reduces processing cost with increased patient compliance, he added. The start-up completed the bio equivalence study which was approved by Drugs Controller General of India (DCGI) in September 2020, Khandare said. Click the link below to read the full article. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe